Literature DB >> 24984200

The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.

Michele Zampieri1, Fabio Ciccarone1, Rocco Palermo2, Samantha Cialfi3, Claudio Passananti4, Sabina Chiaretti5, Daniela Nocchia5, Claudio Talora3, Isabella Screpanti6, Paola Caiafa7.   

Abstract

Aberrant upregulation of NOTCH3 gene plays a critical role in cancer pathogenesis. However, the underlying mechanisms are still unknown. We tested here the hypothesis that aberrant epigenetic modifications in the NOTCH3 promoter region might account for its upregulation in cancer cells. We compared DNA and histone methylation status of NOTCH3 promoter region in human normal blood cells and T cell acute lymphoblastic leukemia (T-ALL) cell lines, differentially expressing NOTCH3. We found that histone methylation, rather than DNA hypomethylation, contributes towards establishing an active chromatin status of NOTCH3 promoter in NOTCH3 overexpressing cancer cells. We discovered that the chromatin regulator protein BORIS/CTCFL plays an important role in regulating NOTCH3 gene expression. We observed that BORIS is present in T-ALL cell lines as well as in cell lines derived from several solid tumors overexpressing NOTCH3. Moreover, BORIS targets NOTCH3 promoter in cancer cells and it is able to induce and to maintain a permissive/active chromatin conformation. Importantly, the association between NOTCH3 overexpression and BORIS presence was confirmed in primary T-ALL samples from patients at the onset of the disease. Overall, our results provide novel insights into the determinants of NOTCH3 overexpression in cancer cells, by revealing a key role for BORIS as the main mediator of transcriptional deregulation of NOTCH3.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer testis antigen; Chromatin; DNA/histone methylation; Oncogene; T cell acute lymphoblastic leukemia

Mesh:

Substances:

Year:  2014        PMID: 24984200     DOI: 10.1016/j.bbagrm.2014.06.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

2.  Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Authors:  Jason Roszik; Anil K Sood; Alejandro Villar-Prados; Sherry Y Wu; Karem A Court; Shaolin Ma; Christopher LaFargue; Mamur A Chowdhury; Margaret I Engelhardt; Cristina Ivan; Prahlad T Ram; Ying Wang; Keith Baggerly; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Shyh Ming-Yang; David J Maloney; Makoto Yoshioka; Jeffrey W Strovel
Journal:  Mol Cancer Ther       Date:  2018-11-12       Impact factor: 6.261

Review 3.  CTCF and CTCFL in cancer.

Authors:  Roxanne E Debaugny; Jane A Skok
Journal:  Curr Opin Genet Dev       Date:  2020-04-22       Impact factor: 5.578

4.  Choice of binding sites for CTCFL compared to CTCF is driven by chromatin and by sequence preference.

Authors:  Philipp Bergmaier; Oliver Weth; Sven Dienstbach; Thomas Boettger; Niels Galjart; Marco Mernberger; Marek Bartkuhn; Rainer Renkawitz
Journal:  Nucleic Acids Res       Date:  2018-08-21       Impact factor: 16.971

5.  PTENα and PTENβ promote carcinogenesis through WDR5 and H3K4 trimethylation.

Authors:  Shao-Ming Shen; Cheng Zhang; Meng-Kai Ge; Shuang-Shu Dong; Li Xia; Ping He; Na Zhang; Yan Ji; Shuo Yang; Yun Yu; Jun-Ke Zheng; Jian-Xiu Yu; Qiang Xia; Guo-Qiang Chen
Journal:  Nat Cell Biol       Date:  2019-11-04       Impact factor: 28.824

6.  Ageing affects subtelomeric DNA methylation in blood cells from a large European population enrolled in the MARK-AGE study.

Authors:  Maria Giulia Bacalini; Anna Reale; Marco Malavolta; Fabio Ciccarone; María Moreno-Villanueva; Martijn E T Dollé; Eugène Jansen; Tilman Grune; Efstathios S Gonos; Christiane Schön; Jürgen Bernhardt; Beatrix Grubeck-Loebenstein; Ewa Sikora; Olivier Toussaint; Florence Debacq-Chainiaux; Miriam Capri; Antti Hervonen; Mikko Hurme; P Eline Slagboom; Nicolle Breusing; Valentina Aversano; Stefano Tagliatesta; Claudio Franceschi; Maria A Blasco; Alexander Bürkle; Paola Caiafa; Michele Zampieri
Journal:  Geroscience       Date:  2021-04-19       Impact factor: 7.713

Review 7.  Epigenetic mechanisms in cancer: push and pull between kneaded erasers and fate writers.

Authors:  Ammad Ahmad Farooqi; Jen-Yang Tang; Ruei-Nian Li; Muhammad Ismail; Yung-Ting Chang; Chih-Wen Shu; Shyng-Shiou F Yuan; Jing-Ru Liu; Qaisar Mansoor; Chih-Jen Huang; Hsueh-Wei Chang
Journal:  Int J Nanomedicine       Date:  2015-04-24

8.  A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.

Authors:  Se-Lyun Yoon; Yun-Gil Roh; In-Sun Chu; Jeonghoon Heo; Seung Il Kim; Heekyung Chang; Tae-Hong Kang; Jin Woong Chung; Sang Seok Koh; Vladimir Larionov; Sun-Hee Leem
Journal:  Exp Mol Med       Date:  2016-07-15       Impact factor: 8.718

9.  Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression.

Authors:  G Franciosa; G Diluvio; F Del Gaudio; M V Giuli; R Palermo; P Grazioli; A F Campese; C Talora; D Bellavia; G D'Amati; Z M Besharat; C Nicoletti; C W Siebel; L Choy; A Rustighi; G Del Sal; I Screpanti; S Checquolo
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

10.  Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.

Authors:  Takuya Asano; Yoshihiko Hirohashi; Toshihiko Torigoe; Tasuku Mariya; Ryota Horibe; Takafumi Kuroda; Yuta Tabuchi; Hiroshi Saijo; Kazuyo Yasuda; Masahito Mizuuchi; Akari Takahashi; Hiroko Asanuma; Tadashi Hasegawa; Tsuyoshi Saito; Noriyuki Sato
Journal:  Oncotarget       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.